Voyager Therapeutics Has Selected A Lead Development Candidate For Its Superoxide Dismutase 1-mutated Amyotrophic Lateral Sclerosis Gene Therapy Program; FDA Investigational New Drug Application Filing Anticipated In Mid-2025
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics has chosen a lead candidate for its gene therapy program targeting Superoxide Dismutase 1-mutated Amyotrophic Lateral Sclerosis (ALS). The company expects to file an Investigational New Drug (IND) application with the FDA by mid-2025.
December 06, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Voyager Therapeutics has announced progress in its ALS gene therapy program, with a lead candidate selected and an IND filing with the FDA anticipated by mid-2025.
The selection of a lead development candidate for Voyager Therapeutics' gene therapy program is a significant milestone, indicating progress in their research and development. The anticipation of an IND filing with the FDA by mid-2025 suggests a clear regulatory pathway ahead. This news is likely to be viewed positively by investors, as it reflects advancement towards potential commercialization. However, the impact is moderated by the timeline, with the filing still over two years away.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100